Sun Pharmaceutical Industries logo

Sun Pharmaceutical Industries

India (Mumbai) • Manufacturer

Sun Pharmaceutical Industries is a manufacturer of peptides based in India (Mumbai). Direct manufacturer. Founded 1983. Key products include peptide APIs, generic APIs.

FDA warning letter
The U.S. FDA sent Sun Pharmaceutical Industries a warning letter dated June 18, 2024 (CGMP, finished pharmaceuticals; Dadra facility, not a peptide API site). Read the letter on fda.gov. A warning letter is not a court ruling, and companies can respond to it; check fda.gov for any close-out letter.
ConfidenceMedium
Business TypeManufacturer
ModelManufacturer
RegionAsia
Founded1983
Verification status based on publicly available information and supplier-provided materials.

Listing reviewed October 2026.

Is this your company? Claim this listing to update your info and get a verified badge.Claim This Listing

Mumbai-based maker of generic and specialty medicines and their APIs, which describes itself as India's No. 1 pharmaceutical company. Holds active US Drug Master Files for semaglutide and liraglutide API.

Directory assessment: Sun Pharmaceutical Industries is listed as a manufacturer in the peptide supply chain, serving Asia markets from India (Mumbai). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 2 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.

Products (4)
Capabilities
US Drug Master Files
  • Semaglutide: DMF 36345 (Type II, active), submitted 2021-10-15
  • Liraglutide: DMF 36549 (Type II, active), submitted 2021-12-30

DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-15.